Skip to main content

IMCD Malaysia acquires Euro Chemo-Pharma to accelerate growth in life science markets

Written by Customer Service on . Posted in Mergers And Acquisitions.

Photo – IMCD Malaysia acquires Euro Chemo-Pharma to accelerate growth in life science markets

In picture, from left to right- Fenna van Zanten, Global Director M&A of IMCD Group- Jeryl Tan, Executive Director of Euro Chemo-Pharma- Teoh Seok Har, Director of Euro Chemo-Pharma- Tan Hooi Pheng, Founder and Managing Director of Euro Chemo-Pharma- Andreas Igerl, President of IMCD APAC- Vivien Tan, Executive Director of Euro Chemo-Pharma- Sylvia Tan, Shareholder of Euro Chemo-Pharma- Emmanuel Colette, APAC Business Group Director of IMCD Food & Nutrition
In picture, from left to right- Fenna van Zanten, Global Director M&A of IMCD Group- Jeryl Tan, Executive Director of Euro Chemo-Pharma- Teoh Seok Har, Director of Euro Chemo-Pharma- Tan Hooi Pheng, Founder and Managing Director of Euro Chemo-Pharma- Andreas Igerl, President of IMCD APAC- Vivien Tan, Executive Director of Euro Chemo-Pharma- Sylvia Tan, Shareholder of Euro Chemo-Pharma- Emmanuel Colette, APAC Business Group Director of IMCD Food & Nutrition

ROTTERDAM, The Netherlands (19 May 2023) – IMCD N.V. (“IMCD” or “Company”), a leading distributor, formulator, and solutions provider of speciality chemicals and ingredients, today announces that IMCD has signed an agreement to acquire 100% of the shares of the speciality distribution company, Euro Chemo-Pharma Sdn Bhd (“Euro Chemo-Pharma”) and its wholly owned subsidiary, Biofresh Green Sdn Bhd (“Biofresh”).

Euro Chemo-Pharma was founded in Malaysia in 1975, offering a wide range of products, mainly food, pharmaceutical and personal care applications. Headquartered in Penang, with offices and warehouses also in Kuala Lumpur and Johor, it ensures the full coverage of the Malaysian market. The company also represents leading global suppliers providing its customers with an extensive portfolio backed by in-depth formulation expertise. With a generated revenue of approximately MYR 270 million (ca. EUR 55 million) in the financial year that ended on June 30, 2022, Euro Chemo-Pharma adds approximately 124 employees to the IMCD Malaysia team and an application laboratory in Penang.

Additionally, Euro Chemo-Pharma’s subsidiary, Biofresh, includes blending, mixing, and compounding of food and flavour ingredients and holds the Halal certification.

“Euro Chemo-Pharma’s strategic positioning is fully aligned with IMCD, providing us the complementary portfolio to accelerate growth in the Malaysian market,” remarked Andreas Igerl, President at IMCD APAC. “In addition, we aim to leverage the suppliers’ synergies we gain from them to develop further our life science business in the Asia Pacific markets,” concluded Igerl.    

“We have managed to grow the company to be the largest and most efficient speciality ingredients distributor in Malaysia,” commented Jeryl Tan, Executive Director at Euro Chemo-Pharma. “With the mindset that if you don’t step forward, you are always in the same place, we believe that IMCD would be our best partner in the journey to drive growth and provide an exciting new home for our people,” concluded Tan.

The closing of the transaction is subject to customary closing conditions and is expected to take place in the last quarter of 2023.

Attached, the press release in pdf format, the main visual, and the photo caption.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.